B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
Open Access
- 2 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12), e0242559
- https://doi.org/10.1371/journal.pone.0242559
Abstract
Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion.Funding Information
- National Major Science and Technology Projects of China (2017ZX10202201; 2017ZX10201021-001-008; 2017ZX10302201-004-003; 2017ZX10202203-006)
- National Natural Science Foundation of China (81900537)
- Capital Foundation of Medical Development (2018-2-2183)
- The Capital Characteristic Clinical Application Research (Z171100001017062)
- Beijing Municipal Natural Science Foundation (7182073)
This publication has 17 references indexed in Scilit:
- Understanding the human antibody repertoiremAbs, 2020
- Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis BJournal of Hepatology, 2019
- Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infectionReviews in Medical Virology, 2018
- A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alphaHepatology, 2017
- Antibody-mediated immunotherapy against chronic hepatitis B virus infectionHuman Vaccines & Immunotherapeutics, 2017
- Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patientsCellular & Molecular Immunology, 2015
- Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infectionJournal of Gastroenterology and Hepatology, 2012
- Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infectionGut, 2011
- Increased frequency of CD56Bright NK‐cells, CD3−CD16+CD56− NK‐cells and activated CD4+T‐cells or B‐cells in parallel with CD4+CDC25High T‐cells control potentially viremia in blood donors with HCVJournal of Medical Virology, 2008
- Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease.2005